Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and calls has predictably returned. To cope, yes, we are quaffing cups of stimulation — our flavor at the moment is mocha nut fudge — and invite you to join us. And why not? The neurons can use all the help they can get. Meanwhile, here are a few tidbits to help you on your journey. Hope your day is successful and please do keep in touch. …

Many of the nation’s largest drug makers and distributors failed to implement even the most basic systems to halt suspicious drug orders as the opioid epidemic came into sharp focus, The Wall Street Journal writes, citing a court filing. The motion by lawyers for two Ohio counties alleges companies failed to analyze potentially suspicious orders until after they had shipped, applied rudimentary controls on excessive sales that were easy for bad actors to game, and handed the job of halting shady orders to sales departments incentivized to keep pills moving.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Concerning Amgen and Allergan – when the first interest in biosimilar came 10 years ago, it was disheartening to many that 50% savings were “totally unrealistic.” The projected savings would be 30 pct, which would still be a savings against the much higher costs. Now 15% is being touted – what will come next, a target of price parity with the branded biologics?

Comments are closed.